Epigenetic and immune drugs join forces against tough tumors
NCT ID NCT04705818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo shrank or stabilized tumors. The goal is to find a new way to treat cancers that don't respond to standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab and tazemetostat
- What this could lead to
- If successful, this combination could offer a new treatment option for several hard-to-treat cancers, potentially slowing or stopping tumor growth.
- What could go wrong
- This is a Phase 2 trial with modest enrollment (164 participants). The results may not apply to all cancer types, and side effects from the drug combination could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Brest
Brest, 29200, France
-
CHU Poitiers
Poitiers, 86000, France
-
Institut Bergonie
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?